동종 세포 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향 예측(2024-2031년)

Persistence Market Research has recently released a comprehensive report on the worldwide market for Allogeneic Cell Therapy. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global allogeneic cell therapy market from 2024 to 2031.

Key Insights:

• Allogeneic Cell Therapy Market Size (2024E):US$0.4 Bn
• Projected Market Value (2031F): US$2.4 Bn
• Global Market Growth Rate (CAGR 2024 to 2031):24.1%

Allogeneic Cell Therapy Market - Report Scope:

Allogeneic cell therapy involves the use of cells from a donor to treat various medical conditions, offering a promising solution for conditions like cancer, autoimmune diseases, and genetic disorders. This therapy is rapidly gaining traction across hospitals, research institutions, and specialized clinics. The allogeneic cell therapy market spans applications in oncology, regenerative medicine, cardiovascular treatment, and immunotherapy, addressing unmet medical needs through stem cell-based approaches. Market growth is driven by advancements in cell engineering, the increasing incidence of chronic diseases, and the development of innovative therapeutic platforms.

Market Growth Drivers:

The global allogeneic cell therapy market is propelled by several key factors, including the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and autoimmune conditions, which are fueling demand for advanced therapies. Technological innovations in cell-based therapies, coupled with regulatory approvals of novel products, are accelerating market growth. Increased investments in R&D and the growing recognition of allogeneic cell therapy's potential to address complex medical conditions without the need for patient-derived cells further support market expansion.

Market Restraints:

Despite the promising growth outlook, the allogeneic cell therapy market faces challenges related to regulatory hurdles, high production costs, and logistical complexities of cell manufacturing and distribution. Stringent regulatory requirements for clinical trials, coupled with concerns over immune rejection and long-term safety, present barriers to widespread adoption. Additionally, the cost of cell therapies remains high, limiting accessibility, particularly in emerging economies with constrained healthcare budgets. Addressing these challenges requires collaborative efforts between stakeholders, including regulatory bodies, manufacturers, and healthcare providers, to streamline production processes and reduce costs.

Market Opportunities:

The allogeneic cell therapy market presents significant growth opportunities driven by advancements in gene editing technologies, the rise of personalized medicine, and increased government funding for cell-based research. The integration of artificial intelligence (AI) and data analytics into cell therapy research is expected to optimize treatment outcomes and reduce time-to-market for new therapies. Furthermore, the growing application of allogeneic cell therapies in treating diseases beyond oncology, such as neurological disorders and autoimmune diseases, expands market potential. Strategic collaborations and partnerships with academic institutions and biotechnology companies are essential to drive innovation and maintain market leadership.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the allogeneic cell therapy market globally?
• Which therapeutic areas are driving allogeneic cell therapy adoption across different healthcare settings?
• How are technological advancements reshaping the competitive landscape of the allogeneic cell therapy market?
• Who are the key players contributing to the allogeneic cell therapy market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global allogeneic cell therapy market?

Competitive Intelligence and Business Strategy:

Leading players in the global allogeneic cell therapy market, including Mesoblast Limited, JCR Pharmaceuticals Co., Ltd., and Athersys, Inc., focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced cell therapies for diverse applications such as regenerative medicine and oncology. Collaborations with research institutions, pharmaceutical companies, and regulatory agencies facilitate market access and promote technology adoption. Moreover, emphasis on clinical research, evidence-based practice, and patient education fosters market growth and enhances treatment outcomes in the rapidly evolving cell therapy landscape.

Key Companies Profiled:

• Mesoblast Limited
• JCR Pharmaceuticals Co., Ltd.
• Athersys, Inc.
• AlloVir
• Gamida Cell Ltd.
• Atara Biotherapeutics, Inc.
• Celyad Oncology

Allogeneic Cell Therapy Market Segmentation

By Therapy Type

• Stem Cell Therapies
• Non-stem Cell Therapies

By Therapeutic Area

• Hematological Disorders
• Dermatological Disorders
• Oncological Disorders
• Neurological Disorders

By Region

• North America
• Europe
• Asia Pacific
• the Middle East and Africa
• Latin America

Table of Contents

1. Executive Summary

• 1.1. Global Allogeneic Cell Therapy Market Snapshot, 2024-2031
• 1.2. Market Opportunity Assessment, 2024-2031, US$ Bn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
  • 2.3.3. Global Healthcare Spending Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Epidemiology - Disease Prevalence and Incidence
• 3.2. Technology Assessment
• 3.3. Regulatory Landscape
• 3.4. Value Chain Analysis
• 3.5. Key Deals and Mergers
• 3.6. PESTLE Analysis
• 3.7. Porter's Five Force Analysis

4. Global Allogeneic Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Bn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
  • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024-2031
• 4.3. Global Allogeneic Cell Therapy Market Outlook: Therapy Type
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Therapy Type, 2019-2023
  • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Therapy Type, 2024-2031
    • 4.3.3.1. Stem Cell Therapies
    • 4.3.3.2. Non-stem Cell Therapies
• 4.4. Market Attractiveness Analysis: Therapy Type
• 4.5. Global Allogeneic Cell Therapy Market Outlook: Therapeutic Area
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Therapeutic Area, 2019-2023
  • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2024-2031
    • 4.5.3.1. Hematological Disorders
    • 4.5.3.2. Dermatological Disorders
    • 4.5.3.3. Oncological Disorders
    • 4.5.3.4. Neurological Disorders
    • 4.5.3.5. Others
• 4.6. Market Attractiveness Analysis: Therapeutic Area

5. Global Allogeneic Cell Therapy Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
• 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2031
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Allogeneic Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 6.1. Key Highlights
• 6.2. Pricing Analysis
• 6.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 6.3.1. By Country
  • 6.3.2. By Therapy Type
  • 6.3.3. By Therapeutic Area
• 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 6.4.1. U.S.
  • 6.4.2. Canada
• 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapy Type, 2024-2031
  • 6.5.1. Stem Cell Therapies
  • 6.5.2. Non-stem Cell Therapies
• 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2024-2031
  • 6.6.1. Hematological Disorders
  • 6.6.2. Dermatological Disorders
  • 6.6.3. Oncological Disorders
  • 6.6.4. Neurological Disorders
  • 6.6.5. Others
• 6.7. Market Attractiveness Analysis

7. Europe Allogeneic Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 7.1. Key Highlights
• 7.2. Pricing Analysis
• 7.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 7.3.1. By Country
  • 7.3.2. By Therapy Type
  • 7.3.3. By Therapeutic Area
• 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 7.4.1. Germany
  • 7.4.2. France
  • 7.4.3. U.K.
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Russia
  • 7.4.7. Turkiye
  • 7.4.8. Rest of Europe
• 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapy Type, 2024-2031
  • 7.5.1. Stem Cell Therapies
  • 7.5.2. Non-stem Cell Therapies
• 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2024-2031
  • 7.6.1. Hematological Disorders
  • 7.6.2. Dermatological Disorders
  • 7.6.3. Oncological Disorders
  • 7.6.4. Neurological Disorders
  • 7.6.5. Others
• 7.7. Market Attractiveness Analysis

8. East Asia Allogeneic Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 8.1. Key Highlights
• 8.2. Pricing Analysis
• 8.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 8.3.1. By Country
  • 8.3.2. By Therapy Type
  • 8.3.3. By Therapeutic Area
• 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. South Korea
• 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapy Type, 2024-2031
  • 8.5.1. Stem Cell Therapies
  • 8.5.2. Non-stem Cell Therapies
• 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2024-2031
  • 8.6.1. Hematological Disorders
  • 8.6.2. Dermatological Disorders
  • 8.6.3. Oncological Disorders
  • 8.6.4. Neurological Disorders
  • 8.6.5. Others
• 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Allogeneic Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 9.1. Key Highlights
• 9.2. Pricing Analysis
• 9.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 9.3.1. By Country
  • 9.3.2. By Therapy Type
  • 9.3.3. By Therapeutic Area
• 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 9.4.1. India
  • 9.4.2. Southeast Asia
  • 9.4.3. ANZ
  • 9.4.4. Rest of South Asia & Oceania
• 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapy Type, 2024-2031
  • 9.5.1. Stem Cell Therapies
  • 9.5.2. Non-stem Cell Therapies
• 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2024-2031
  • 9.6.1. Hematological Disorders
  • 9.6.2. Dermatological Disorders
  • 9.6.3. Oncological Disorders
  • 9.6.4. Neurological Disorders
  • 9.6.5. Others
• 9.7. Market Attractiveness Analysis

10. Latin America Allogeneic Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 10.1. Key Highlights
• 10.2. Pricing Analysis
• 10.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 10.3.1. By Country
  • 10.3.2. By Therapy Type
  • 10.3.3. By Therapeutic Area
• 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 10.4.1. Brazil
  • 10.4.2. Mexico
  • 10.4.3. Rest of Latin America
• 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapy Type, 2024-2031
  • 10.5.1. Stem Cell Therapies
  • 10.5.2. Non-stem Cell Therapies
• 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2024-2031
  • 10.6.1. Hematological Disorders
  • 10.6.2. Dermatological Disorders
  • 10.6.3. Oncological Disorders
  • 10.6.4. Neurological Disorders
  • 10.6.5. Others
• 10.7. Market Attractiveness Analysis

11. Middle East & Africa Allogeneic Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 11.1. Key Highlights
• 11.2. Pricing Analysis
• 11.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 11.3.1. By Country
  • 11.3.2. By Therapy Type
  • 11.3.3. By Therapeutic Area
• 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 11.4.1. GCC Countries
  • 11.4.2. Egypt
  • 11.4.3. South Africa
  • 11.4.4. Northern Africa
  • 11.4.5. Rest of Middle East & Africa
• 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapy Type, 2024-2031
  • 11.5.1. Stem Cell Therapies
  • 11.5.2. Non-stem Cell Therapies
• 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2024-2031
  • 11.6.1. Hematological Disorders
  • 11.6.2. Dermatological Disorders
  • 11.6.3. Oncological Disorders
  • 11.6.4. Neurological Disorders
  • 11.6.5. Others
• 11.7. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2024
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. SSM Cardinal Glennon Children's Medical Center
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Cleveland Cord Blood Center
    • 12.3.2.1. Overview
    • 12.3.2.2. Segments and Products
    • 12.3.2.3. Key Financials
    • 12.3.2.4. Market Developments
    • 12.3.2.5. Market Strategy
  • 12.3.3. Duke University School of Medicine
    • 12.3.3.1. Overview
    • 12.3.3.2. Segments and Products
    • 12.3.3.3. Key Financials
    • 12.3.3.4. Market Developments
    • 12.3.3.5. Market Strategy
  • 12.3.4. New York Blood Center
    • 12.3.4.1. Overview
    • 12.3.4.2. Segments and Products
    • 12.3.4.3. Key Financials
    • 12.3.4.4. Market Developments
    • 12.3.4.5. Market Strategy
  • 12.3.5. Clinimmune Labs, University of Colorado Cord Blood Bank
    • 12.3.5.1. Overview
    • 12.3.5.2. Segments and Products
    • 12.3.5.3. Key Financials
    • 12.3.5.4. Market Developments
    • 12.3.5.5. Market Strategy
  • 12.3.6. MD Anderson Cord Blood Bank
    • 12.3.6.1. Overview
    • 12.3.6.2. Segments and Products
    • 12.3.6.3. Key Financials
    • 12.3.6.4. Market Developments
    • 12.3.6.5. Market Strategy
  • 12.3.7. LifeSouth Community Blood Centers, Inc.
    • 12.3.7.1. Overview
    • 12.3.7.2. Segments and Products
    • 12.3.7.3. Key Financials
    • 12.3.7.4. Market Developments
    • 12.3.7.5. Market Strategy
  • 12.3.8. Bloodworks Northwest
    • 12.3.8.1. Overview
    • 12.3.8.2. Segments and Products
    • 12.3.8.3. Key Financials
    • 12.3.8.4. Market Developments
    • 12.3.8.5. Market Strategy
  • 12.3.9. JCR Pharmaceuticals Co., Ltd.
    • 12.3.9.1. Overview
    • 12.3.9.2. Segments and Products
    • 12.3.9.3. Key Financials
    • 12.3.9.4. Market Developments
    • 12.3.9.5. Market Strategy
  • 12.3.10. Sumitomo Pharma Co., Ltd.
    • 12.3.10.1. Overview
    • 12.3.10.2. Segments and Products
    • 12.3.10.3. Key Financials
    • 12.3.10.4. Market Developments
    • 12.3.10.5. Market Strategy
  • 12.3.11. Atara Biotherapeutics
    • 12.3.11.1. Overview
    • 12.3.11.2. Segments and Products
    • 12.3.11.3. Key Financials
    • 12.3.11.4. Market Developments
    • 12.3.11.5. Market Strategy
  • 12.3.12. Mallinckrodt Pharmaceuticals
    • 12.3.12.1. Overview
    • 12.3.12.2. Segments and Products
    • 12.3.12.3. Key Financials
    • 12.3.12.4. Market Developments
    • 12.3.12.5. Market Strategy
  • 12.3.13. Tego Science Inc
    • 12.3.13.1. Overview
    • 12.3.13.2. Segments and Products
    • 12.3.13.3. Key Financials
    • 12.3.13.4. Market Developments
    • 12.3.13.5. Market Strategy
  • 12.3.14. Takeda Pharmaceutical Company Limited
    • 12.3.14.1. Overview
    • 12.3.14.2. Segments and Products
    • 12.3.14.3. Key Financials
    • 12.3.14.4. Market Developments
    • 12.3.14.5. Market Strategy
  • 12.3.15. STEMPEUTICS RESEARCH PVT LTD
    • 12.3.15.1. Overview
    • 12.3.15.2. Segments and Products
    • 12.3.15.3. Key Financials
    • 12.3.15.4. Market Developments
    • 12.3.15.5. Market Strategy
  • 12.3.16. Biosolution Co., Ltd.
    • 12.3.16.1. Overview
    • 12.3.16.2. Segments and Products
    • 12.3.16.3. Key Financials
    • 12.3.16.4. Market Developments
    • 12.3.16.5. Market Strategy
  • 12.3.17. MEDIPOST Co., Ltd.
    • 12.3.17.1. Overview
    • 12.3.17.2. Segments and Products
    • 12.3.17.3. Key Financials
    • 12.3.17.4. Market Developments
    • 12.3.17.5. Market Strategy

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations